NEW YORK, April 01, 2016 -- Wolf Haldenstein Adler Freeman & Herz LLP (“Wolf Haldenstein”) announces that it has filed a class action lawsuit in the United States District Court for the District of Utah (the "Court"), on behalf of the shareholders of Questar Corporation ("Questar") (NYSE:STR) against Questar, its Board of Directors, and Dominion Resources, Inc. ("Dominion"), for, among other things, violations of sections 14(a) and 20(a) of the U.S. Securities and Exchange Act of 1934 (the "Exchange Act") and U.S. Securities and Exchange Commission Rule 14a-9 promulgated thereunder.
The complaint arises out of a February 1, 2016 press release announcing that Questar had entered into a definitive merger agreement with Dominion, pursuant to which Questar shareholders would receive $25.00 for each share of Questar owned (the "Proposed Transaction"). The complaint seeks injunctive relief on behalf of the named plaintiffs and all other similarly situated shareholders of Questar as of February 1, 2014 (the "Class"). The named plaintiff is represented by Wolf Haldenstein.
If you owned shares of Questar Corporation prior to February 1, 2016, and still hold your shares, you may, no later than May 31, 2016, request that the Court appoint you lead plaintiff of the proposed class.
The named plaintiff alleges that certain of the defendants, in connection with the Proposed Transaction, breached or aided and abetted the other defendants' breaches of their duties and obligations owed to Questar shareholders. The complaint further alleges that, in an attempt to secure shareholder approval of the Proposed Transaction, the defendants filed a materially false and misleading proxy statement on Form 14 with the U.S. Securities and Exchange Commission in violation of the Exchange Act and their duties of candor and full disclosure. The omitted and/or misrepresented information is believed to be material to Questar shareholders' ability to make an informed decision whether to approve the Proposed Transaction.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at [email protected]
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Gloria Kui Melwani, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774


ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 



